SCHEMBL3540666

SCHEMBL3540666

CN1C2CCC1CN(c1ccc3cc([N+](=O)[O-])ccc3n1)C2

nearest known ligand 0.63

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.60
HTR3E A5X5Y0 1/20 0.60
HTR3B O95264 1/20 0.60
CYP1A2 P05177 1/20 0.60
CYP3A4 P08684 1/20 0.60
SLC6A4 P31645 1/20 0.60
CYP2C19 P33261 1/20 0.60
THPO P40225 1/20 0.60
HTR3A P46098 1/20 0.60
HTR3D Q70Z44 1/20 0.60
HTR3C Q8WXA8 1/20 0.60
LMNA P02545 1/20 0.52
PMP22 Q01453 1/20 0.52
NPSR1 Q6W5P4 1/20 0.52
HTR1A P08908 8/20 0.52
MAPT P10636 1/20 0.43
HRH3 Q9Y5N1 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3386080 0.95 ALDH1A1 (0.58) ALDH1A1HTR3EHTR3BCYP1A2CYP3A4
SCHEMBL5832121 0.93 ALDH1A1 (0.59) ALDH1A1HTR3EHTR3BCYP1A2CYP3A4
SCHEMBL27480804 0.89 ALDH1A1 (0.57) ALDH1A1HTR3EHTR3BCYP1A2CYP3A4
SCHEMBL3541348 0.82 ALDH1A1 (0.64) ALDH1A1HTR3EHTR3BCYP1A2CYP3A4
SCHEMBL3542103 0.82 ALDH1A1 (0.49) ALDH1A1HTR3EHTR3BCYP1A2CYP3A4
SCHEMBL4688608 0.82 ALDH1A1 (0.54) ALDH1A1HTR3EHTR3BCYP1A2CYP3A4
SCHEMBL3382640 0.81 ALDH1A1 (0.61) ALDH1A1HTR3EHTR3BCYP1A2CYP3A4
SCHEMBL5873479 0.80 ALDH1A1 (0.54) ALDH1A1HTR3EHTR3BCYP1A2CYP3A4
SCHEMBL4472746 0.78 ALDH1A1 (0.56) ALDH1A1HTR3EHTR3BCYP1A2CYP3A4
SCHEMBL3384126 0.78 ALDH1A1 (0.47) ALDH1A1HTR3EHTR3BCYP1A2CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7704991-B2 Substituted diazabicyclo derivatives and their use as monoamine neurotransmitter re-uptake inhibitors NEUROSEARCH A/S (DK) 2010-04-27 US claimed
US-20080280882-A1 Novel Substituted Diazabicyclo Derivatives and Their Use as Monoamine Neurotransmitter Re-Uptake Inhibitors NEUROSEARCH A/S (DK) 2008-11-13 US claimed
EP-1869050-A1 NOVEL SUBSTITUTED DIAZABICYCLO DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS NEUROSEARCH A/S (DK) 2007-12-26 EP claimed
WO-2006106090-A1 NOVEL SUBSTITUTED DIAZABICYCLO DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS NEUROSEARCH A/S (DK) 2006-10-12 WO claimed
US-7704991-B2 Substituted diazabicyclo derivatives and their use as monoamine neurotransmitter re-uptake inhibitors NEUROSEARCH A/S (DK) 2010-04-27 US disclosed
US-20080280882-A1 Novel Substituted Diazabicyclo Derivatives and Their Use as Monoamine Neurotransmitter Re-Uptake Inhibitors NEUROSEARCH A/S (DK) 2008-11-13 US disclosed
EP-1869050-A1 NOVEL SUBSTITUTED DIAZABICYCLO DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS NEUROSEARCH A/S (DK) 2007-12-26 EP disclosed
WO-2006106090-A1 NOVEL SUBSTITUTED DIAZABICYCLO DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS NEUROSEARCH A/S (DK) 2006-10-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080280882-A1 Novel Substituted Diazabicyclo Derivatives and Their Use as Monoamine Neurotransmitter Re-Uptake Inhibitors SLC18A2, SLC6A2, SLC6A3 ALDH1A1 780/4885HTR3E 162/4885HTR3B 40/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.